Close Menu

NEW YORK ─ Bio-Techne and Regulus Therapeutics on Wednesday announced a collaboration to support biomarker assay development and biomarker analysis for the clinical development of Regulus' RGLS4326, an autosomal dominant polycystic kidney disease (ADPKD) treatment.

Regulus has used two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to help with its clinical trial patient testing, Bio-Techne said. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.